54.31 USD
↘ 0.37 (0.68%)AT CLOSE (11:59 AM EDT)
AnaptysBio, Inc. Common Stock
ANABNASDAQ • USD
54.29
↘ 0.02 (0.04%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
54.29
↘ 0.02 (0.04%)
Market: CLOSED
AnaptysBio, Inc. Common Stock (ANAB) trades at $54.33 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Sep 16, 2026.
Open?$54.44
High?$54.80
Low?$53.62
Prev. Close?$54.68
Volume?394.1K
Avg. Volume?419.6K
VWAP?$54.12
Rel. Volume?0.94x
Bid / Ask
Bid?$50.48 × 100
Ask?$64.55 × 100
Spread?$14.07
Midpoint?$57.52
Valuation & Ratios
Market Cap?1.6B
Shares Out?29.6M
Float?17.5M
Float %?59.0%
P/E Ratio?N/A
P/B Ratio?126.15
EPS?-$0.90
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Employees
104
Market Cap
1.6B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2017-01-26
Address
10770 WATERIDGE CIRCLE, SUITE 210
SAN DIEGO, CA 92121
Phone: 858-362-6295
SAN DIEGO, CA 92121
Phone: 858-362-6295
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?25
Momentum?50
Short Sent.?30
Piotroski F-Score?1/9Weak
Altman Z-Score?1.67Distress
Confidence?65%Moderate
Short InterestSqueeze Risk
Short % of Float?31.00%Squeeze Risk
Short Interest?5.4M
Days to Cover?15.6
Free Float17.5M
Avg Daily Volume347.1K
Settlement Date2026-08-31
Financial Health
Current Ratio?7.58Strong
Quick Ratio?7.58Strong
Cash Ratio?5.96Strong
Debt/Equity?0.00Low
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score47/100
P/E?N/A▾
P/B?126.15HIGH▾
Peers100
S&P3
P/S?6.92FAIR▾
Peers100
S&P17
P/FCF?364.7PRICEY▾
Peers100
S&P3
EV/EBITDA?32.9HIGH▾
Peers100
S&P9
EV/Sales?5.85FAIR▾
Peers100
S&P29
Returns & Efficiency
ROE?-210.1%WEAK▾
S&P3
ROA?-8.1%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$4.4M
Enterprise Value?$1.4B
Fundamentals ratios updated end of day